HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.69 CNY | +1.12% |
|
+6.66% | -22.89% |
| May. 01 | Huluwa Pharmaceutical Gets Nod to Register Two Drugs | MT |
| Apr. 26 | Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Hainan Huluwa Pharmaceutical Group Co Ltd is a China-based company principally involved in the research and development, manufacturing and sales of Chinese patent medicines and chemical drugs. Its products are used in the pharmaceutical fields of respiratory system, digestive system, systemic anti-infection, including pediatric lung heat cough asthma granules, bromhexine hydrochloride for injection, compound Banlangen granules, Keke tablets, omeprazole enteric-coated capsules , Changyanning (capsules and granules), omeprazole sodium for injection, sodium diisopropylamine dichloroacetate for injection and cefixime dispersible tablets, among others. The Company also provides gynecological medicine, cardiovascular system medicine and neurological system medicine preparation products. The Company operates its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -22.89% | 646M | |
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B |
- Stock Market
- Equities
- 605199 Stock
- News Hainan Huluwa Pharmaceutical Group Co., Ltd.
- Huluwa Pharmaceutical Gets Nod to Trial Epilepsy Drug
